logo

For the Inventor, By the Inventor

Carlsbad, CA, United States of America

Xu Bai

This inventor holds 10 USPTO granted patents. Top assignees: Idun Pharmaceuticals, Inc., Bristol-Myers Squibb Pharma Company, Other. Active years: 1999-2004.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Xu Bai. Retrieved from https://idiyas.com/inventor/xu-bai-tkxb5w5m

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 10

% Patents Active = 80.0

Average Co-Inventor Count = 3.2

ph-index = 4

Forward Citations = 66(Granted Patents)


Company Filing History:

goldMedal8 out of 33 
 
Idun Pharmaceuticals, Inc.
 patents
silverMedal1 out of 234 
 
Bristol-Myers Squibb Pharma Company
 patents
bronzeMedal1 out of 834,570 
Other
 patents

Years Active: 1999-2004

Loading Chart...
10 patents (USPTO):Explore Patents
1. 6825208 - Tetrahydroquinoline derivatives as antithrombotic agents (2004-11-30),
2. 6693096 - Treatment of inflammation-associated disorders using interleukin-1&bgr;-converting enzyme (ICE)/CED-3 family inhibitors (2004-02-17),
3. 6610683 - Treatment of infectious disease using interleukin-1&bgr;-converting enzyme (ICE)/CED-3 family inhibitors (2003-08-26),
4. 6531467 - Inhibition of inflammation using interleukin-1&bgr;-converting enzyme (ICE)/CED-3 family inhibitors (2003-03-11),
5. 6528506 - Inhibition of apoptosis using interleukin-1&bgr;-converting enzyme (ICE)/CED-3 family inhibitors (2003-03-04),
6. 6489353 - C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases (2002-12-03),
7. 6200969 - Inhibition of apoptosis using interleukin-1&bgr;-converting enzyme (ICE)/CED-3 family inhibitors (2001-03-13),
8. 6184244 - C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases (2001-02-06),
9. 5877197 - C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors (1999-03-02),
10. 5869519 - C-terminal modified (n-substituted)-2-indolyl dipeptides as inhibitors (1999-02-09),

Title: Xu Bai: Innovator in Antithrombotic and Inflammation Treatments

Introduction

Xu Bai is a prominent inventor based in Carlsbad, California, known for his significant contributions to the field of pharmaceuticals. He holds a total of 10 patents, showcasing his innovative approach to developing new therapeutic agents.

Latest Patents

Among his latest patents, Xu Bai has developed tetrahydroquinoline derivatives as antithrombotic agents. This invention focuses on tetracyclic tetrahydroquinoline compounds, which serve as selective inhibitors of serine protease enzymes, particularly factor VIIa. The patent also includes pharmaceutical compositions containing these compounds and methods for their use as anticoagulant agents to modulate the coagulation cascade. Another notable patent addresses the treatment of inflammation-associated disorders using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors. This invention provides methods and compositions aimed at preventing and treating inflammation-related disorders by suppressing the activity of specific proteases.

Career Highlights

Xu Bai has worked with various companies, including Idun Pharmaceuticals, Inc. His work has significantly impacted the development of new therapeutic strategies in the pharmaceutical industry.

Collaborations

Throughout his career, Xu Bai has collaborated with notable professionals, including Lawrence C. Fritz and Kevin J. Tomaselli. These collaborations have contributed to the advancement of his research and innovations.

Conclusion

Xu Bai's contributions to the field of pharmaceuticals, particularly in antithrombotic and inflammation treatments, highlight his role as a leading inventor. His innovative patents and collaborations continue to influence the development of new therapeutic agents.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…